Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
NCT06522373
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
PI Request
Conditions
Leukemia
Interventions
DRUG:
MT-0169
Sponsor
M.D. Anderson Cancer Center